IRCT20220904055876N1招募中3 期
Efficacy and safety of Tofacitinib versus Azathioprine in severe alopecia areata, alopecia universalis and alopecia totalis.
ady Reading Hospital Peshawar Pakistan0 个研究点目标入组 60 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 12 years 至 60 years（—）
- 性别
- All
入选标准
- •Patients having Alopecia areata with =50% scalp hair loss, Alopecia totalis and Alopecia universalis.
- •Patients must not have received any treatments for Alopecia areata within 2 months of enrollment and will not permitted to use any other treatment known to affect AA
- •Stable or worsening disease for =6 months
排除标准
- •Active malignancy or a history of malignancy
- •Leukopenia, Anemia
- •Hepatic or renal impairment
- •Human immunodeficiency virus, Hepatitis B and C.
- •Pregnant or nursing women
研究者
相似试验
尚未招募
2 期
Comparison of Tofacitinib versus betamethasone oral mini pulse in progressive vitiligoCTRI/2024/02/062634AIIMS, New Delhi
招募中
3 期
Safety and Efficacy of Tofacitinib vs Methotrexate in the Treatment of Psoriatic ArthritisPsoriatic ArthritisPsATCTR20181205001Globe Pharmaceuticals Limited60
招募中
2 期
Baricitinib versus Azathioprine in Moderate-to-Severe Atopic Dermatitis PatientsModerate-to-Severe Atopic Dermatitis Patients.Atopic dermatitisIRCT20160427027636N6Mazandaran University of Medical Sciences40
尚未招募
2 期
se of Tofacitinib and Adalimumab in SpondyloarthritisCTRI/2024/07/071400Indian Rheumatology Association
尚未招募
4 期
sefulness of tofacitinib in atopic dermatitisCTRI/2024/08/072026AIIMS Bhubaneswar